MedTrace Logo

Autologous Cell Therapy for Female Stress Urinary Incontinence

NCT01008943 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-07-01

Study results available
· View outcomes & findings →

Summary

The Autologous Cell Therapy for Female SUI study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million Cook MyoSite Autologous Muscle Derived Cells for treatment of Stress Urinary Incontinence.

Conditions

  • Stress Urinary Incontinence

Interventions

BIOLOGICAL

Autologous Muscle Derived Cells

Urethral injection of autologous muscle-derived cells

Sponsors & Collaborators

  • Cook MyoSite

    lead INDUSTRY

Principal Investigators

  • Lesley K. Carr, MD · Sunnybrook Health Sciences Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-02
Primary Completion
2012-09-21
Completion
2012-09-21

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01008943 on ClinicalTrials.gov